Stories

A subcutaneous implantable cardioverter-defibrillator (S-ICD) protects patients from sudden cardiac death without placing a transvenous lead inside the heart.…

Obesity is increasingly recognised as a modifiable driver of atrial fibrillation (AF), rather than a background characteristic that simply complicates…

Implantable cardioverter-defibrillators (ICDs) remain an important strategy for preventing sudden cardiac death in selected patients with nonischemic…

Persistent atrial fibrillation (AF) is often treated as a disorder sustained by several interacting mechanisms rather than a single, stable source. Electrical…

Cardiac sarcoidosis can create a difficult combination of myocardial inflammation, patchy fibrosis, conduction disease and ventricular arrhythmia. Ventricular…

Pacemaker-mediated tachycardia (PMT) is a rapid, usually regular rhythm produced by an interaction between a dual-chamber pacemaker and the patient’s own…

Hyperkalemia is a common and potentially reversible cause of conduction disturbance, bradyarrhythmia, ventricular tachycardia and cardiac arrest. Its…

Ventricular tachycardia (VT) ablation is technically demanding because the arrhythmogenic substrate may be extensive, intramural, epicardial, or difficult to…

Atrial fibrillation affects roughly 460,000 Australians and accounts for over 60,000 hospital admissions every year, driving stroke and heart failure and…

Subcutaneous implantable cardioverter-defibrillator technology has matured into a mainstream option for adults at risk of sudden cardiac death, but its role in…